Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Selective Serotonin Reuptake Inhibitor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    31 result(s) found for: Selective Serotonin Reuptake Inhibitor. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2019-002992-33 Sponsor Protocol Number: 54135419TRD3013 Start Date*: 2020-08-04
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Open-label, Rater-Blinded, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly Dosed Esketamine Nasal Spray Compared Wit...
    Medical condition: Treatment-Resistant Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) CZ (Completed) PL (Completed) DE (Completed) HU (Completed) FR (Completed) BE (Completed) PT (Completed) BG (Completed) DK (Completed) AT (Completed) NO (Completed) FI (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-021215-16 Sponsor Protocol Number: H9P-MC-LNBQ Start Date*: 2011-02-17
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 mg to 18 mg Once Daily and LY2216684 Fixed-Dose 6 mg Once Daily as Adjunctive Treatment for Patients with Major De...
    Medical condition: Major depressive disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Gender: Male, Female
    Trial protocol: CZ (Completed) FI (Completed) SK (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-005000-17 Sponsor Protocol Number: CAFQ056A2225 Start Date*: 2013-08-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group proof of concept study to evaluate the effect of AFQ056 in obsessive compulsive disorder (OCD) patients resistant to Selective Seroton...
    Medical condition: obsessive compulsive disorder (OCD)
    Disease: Version SOC Term Classification Code Term Level
    12.0 100000004873 10002862 Anxiety disorders NEC (incl obsessive compulsive disorder) HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004509-29 Sponsor Protocol Number: 2012-776 Start Date*: 2015-11-03
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Antidepressant treatments during pregnancy and lactation: prediction of drug exposure through breastfeeding and evaluation of drug effect on the neonatal adaptation and the development of the youn...
    Medical condition: depression
    Disease: Version SOC Term Classification Code Term Level
    18.0 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021216-41 Sponsor Protocol Number: H9P-MC-LNBR(a) Start Date*: 2011-01-24
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who Are Partial Responders...
    Medical condition: Major depressive disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    Population Age: Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) DE (Completed) AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001540-45 Sponsor Protocol Number: EST312007 Start Date*: 2007-06-14
    Sponsor Name:Institute of Psychophysiology and Rehabilitation (IRP) of the Kaunas University of Medicine
    Full Title: Triiodothyronine as an adjunct to accelerate the antidepressant effects of the selective serotonin reuptake inhibitor (SSRI) escitalopram
    Medical condition: Depressive episode
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012402 Depressive episode LLT
    Population Age: Adults Gender: Female
    Trial protocol: LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003654-40 Sponsor Protocol Number: APC031 Start Date*: 2011-10-21
    Sponsor Name:Department of Psychiatry
    Full Title: A Preliminary Study of Intravenous Ketamine in Selective Serotonin Reuptake Inhibitor (SSRI)-Resistant Depression
    Medical condition: Depression
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005860-69 Sponsor Protocol Number: ODEN Start Date*: 2021-05-10
    Sponsor Name:University of Gothenburg
    Full Title: OSU6162 as add-on in SSRI/SNRI-resistant depression (ODEN): a double-blind, placebo-controlled evaluation of efficacy and safety.
    Medical condition: Depression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020726-18 Sponsor Protocol Number: H9P-MC-LNBO Start Date*: 2011-01-17
    Sponsor Name:Eli Lilly and Company
    Full Title: Long-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who are Partial Responders to Selective Serotonin Reuptak...
    Medical condition: Major depressive disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) NL (Completed) ES (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021214-39 Sponsor Protocol Number: H9P-MC-LNBM Start Date*: 2010-12-22
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Placebo-controlled, Double-blind Study of LY2216684 Fixed-dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responder...
    Medical condition: Major depressive disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2011-001436-33 Sponsor Protocol Number: NP25620 Start Date*: 2011-11-22
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, double-blind, parallel-group study of the safety and efficacy of RO4917523 versus placebo, as adjunctive therapy in patients with major depressive disorder with inadequate response to...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10025463 Major depressive disorder, single episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003435-40 Sponsor Protocol Number: CTU 0095 Start Date*: 2006-08-29
    Sponsor Name:Department of Health
    Full Title: A Randomised Controlled Trial to Investigate the effectiveness of the Healthy Sexual Functioning (HSF) Module and Selective Serotonin Reuptake Inhibitor (SSRI) Medication to treat Deviant Sexual Ar...
    Medical condition: Deviant Sexual Arousal (sex offender)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063494 Sexual offence LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004949-41 Sponsor Protocol Number: 1241 Start Date*: 2007-09-11
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: RANDOMIZED DOUBLE-BLIND STUDY TO EVALUATE THE ADJUVANT EFFECT OF POLYNSATURED FATTY ACIDS OMEGA-3 IN THERAPY WITH S.S.R.I. PAROXETINE MESYLATE IN UNIPOLAR MOOD DEPRESSION AND RECURRENT DEPRESSION
    Medical condition: Mood depression
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012374 Depressed mood LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019925-33 Sponsor Protocol Number: D4130C00003 Start Date*: Information not available in EudraCT
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III Efficacy and Safety Study of TC-5214 (S-mecamylamine) in Flexible Doses as an Adjunct to an Antidepressant in ...
    Medical condition: Adjunct treatment to an antidepressant in patients with Major Depressive Disorder who exhibit an inadequate response to antidepressant therapy
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    13.1 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) SE (Completed) LT (Completed) EE (Completed) LV (Completed) CZ (Completed) FR (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-002608-42 Sponsor Protocol Number: PD0004 Start Date*: 2013-01-10
    Sponsor Name:UCB Biosciences GmbH
    Full Title: A Multicenter, Multinational, Double-blind, Placebo-controlled, 2-arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
    Medical condition: Parkinson’s disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2012-002840-26 Sponsor Protocol Number: PD0005 Start Date*: 2013-03-05
    Sponsor Name:UCB Biosciences GmbH
    Full Title: A Multicenter, Multinational, Double-blind, Placebo-controlled, 3-arm Phase 4 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease- Associated Apathy, Motor Symptoms, and Mood
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) HU (Completed) IT (Completed) BG (Completed) SI (Completed) RO (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2010-024137-22 Sponsor Protocol Number: D4130C00004 Start Date*: 2011-02-11
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressa...
    Medical condition: Adjunct treatment to an antidepressant in patients with Major Depressive Disorder who exhibit an inadequate response to antidepressant therapy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005282-22 Sponsor Protocol Number: 42847922MDD2001 Start Date*: 2017-10-24
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Adaptive Dose-Finding Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) BG (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-000337-40 Sponsor Protocol Number: 42847922MDD3001 Start Date*: 2020-09-10
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Eld...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002145-21 Sponsor Protocol Number: 2007003 Start Date*: 2007-12-21
    Sponsor Name:Procter & Gamble Pharmaceuticals
    Full Title: A Phase II, Randomized, Placebo-controlled Study of ATI-7505 in Patients with Chronic Idiopathic Constipation
    Medical condition: Chronic Idiopathic Constipation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063582 Constipation chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) GB (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 04:33:08 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA